Skip to main content
MRK
NYSE Life Sciences

默克-礼来癌症治疗药物未能达成晚期研究目标

feedReported by Reuters
Sentiment info
Negative
Importance info
8
Price
$116.99
Mkt Cap
$289.517B
52W Low
$73.31
52W High
$125.14
Market data snapshot near publication time

summarizeSummary

默克和礼来的实验性联合治疗药物未能达成其晚期研究的主要目标，这对默克公司的肿瘤学管道中的特定药物候选者来说是一个重大挫折，这是公司的一个关键增长领域。虽然默克最近收到了关于其Keytruda药物扩大批准优先审查的积极消息，但这一III期失败代表了一个可能影响未来收入预测和管道估值的重大负面发展。交易者可能会对这一消息做出反应，可能导致股票下行压力，当市场重新评估药物的前景时。投资者应该监测默克公司关于其管道和财务前景的任何更新指南，包括对公司EBITDA、GAAP财务报表、10-K报告、向SEC提交的Form 4和8-K文件以及CIK编号的影响。

在该公告发布时，MRK的交易价格为$116.99，交易所为NYSE，所属行业为Life Sciences，市值约为$2895.2亿。 52周交易区间为$73.31至$125.14。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed MRK - Latest Insights

MRK
Apr 24, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Merck Clears Key Antitrust Hurdle for Terns Pharmaceuticals Acquisition
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 11:50 AM EDT
Source: Reuters
Importance Score:
8
US FDA Approves Merck's New Combination HIV Treatment
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 6:51 AM EDT
Source: Reuters
Importance Score:
8
Merck-Eisai Cancer Therapy Fails Late-Stage Study Goals
Sentiment: Negative
View Wiseek Article
MRK
Apr 20, 2026, 7:29 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
FDA Grants Priority Review to Merck, Pfizer Bladder Cancer Drug Combo
Sentiment: Positive
View Wiseek Article
MRK
Apr 13, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
Merck Actively Pursues Acquisitions to Bolster Pipeline Ahead of Keytruda Patent Expiration
Sentiment: Positive
View Wiseek Article
MRK
Apr 08, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Merck Projects Over $70B Pipeline Opportunity, Details Executive Changes and Annual Meeting Proposals
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C 64.6% in Phase 3, Outperforming Competitors
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 11:48 AM EDT
Source: Reuters
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Decanoate Slashes LDL-C by 64.6%, Earns FDA Priority Voucher
Sentiment: Positive
View Wiseek Article
MRK
Mar 29, 2026, 11:49 AM EDT
Source: Reuters
Importance Score:
8
Merck's Winrevair Hits Phase 2 Endpoint, Advancing to Registrational Phase 3 for Pulmonary Hypertension
Sentiment: Positive
View Wiseek Article
MRK
Mar 25, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Merck Acquires Terns Pharma, Bolstering Hematology Pipeline with Novel CML Candidate TERN-701
Sentiment: Positive
View Wiseek Article